|
|
|
|
|
|
|
|
|
15.10.26 - 14:03
|
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results (Business Wire)
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026, before the U.S. financial markets open.
Management will provide an update on the Company and discuss third quarter 2026 results as well as expectations for the future via conference call on Thursday, October 29, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.08.26 - 13:36
|
Brixton Biosciences Strengthens Board with Industry Veterans as Company Advances Towards Commercialization of Reneurx™ Nerve-Selective Therapy for Pain Associated with Knee Osteoarthritis (Business Wire)
|
|
|
- John Maraganore, Ph.D., Brent Saunders and Elton Brand join Board of Directors -
- Marketing authorization request for Reneurx™ therapy submitted to U.S. FDA; decision anticipated before year end 2026 -CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointment of three new members to its Board of Directors: founding CEO of Alnylam Pharmaceuticals and RNAi pioneer, John Maraganore, Ph.D.; CEO of Bausch + Lomb and biopharma deal-maker, Brent Saunders; and former General Manager, Philadelphia 76ers, Elton Brand. The appointments come as Brixton prepares for U.S. Food and Drug Administration (FDA) marketing authorization and commercialization of its lead investigational product, Reneurx™ Nerve-Selective Therapy.
Reneurx therapy is an investigational first-in-class, nerve-selective biomaterial that is injected around a...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
